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ABSTRACT
Inflammation is a hallmark of HIV infection. Among the multiple stimuli that can induce inflam-
mation in untreated infection, ongoing viral replication is a primary driver. After initiation of
effective combined antiretroviral therapy (cART), HIV replication is drastically reduced or halted.
However, even virologically controlled patients may continue to have abnormal levels of inflam-
mation. A number of factors have been proposed to cause inflammation in HIV infection: among
others, residual (low-level) HIV replication, production of HIV protein or RNA in the absence of
replication, microbial translocation from the gut to the circulation, co-infections, and loss of
immunoregulatory responses. Importantly, chronic inflammation in HIV-infected individuals
increases the risk for a number of non-infectious co-morbidities, including cancer and cardiovas-
cular disease. Thus, achieving a better understanding of the underlying mechanisms of HIV-
associated inflammation in the presence of cART is of utmost importance. Extracellular vesicles
have emerged as novel actors in intercellular communication, involved in a myriad of physiolo-
gical and pathological processes, including inflammation. In this review, we will discuss the role
of extracellular vesicles in the pathogenesis of HIV infection, with particular emphasis on their
role as inducers of chronic inflammation.
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Inflammation and HIV infection
Human Immunodeficiency Virus type 1 (HIV) con-
tinues to threaten global health, with 1.8 million new
infections diagnosed in 2017 [1]. Disruption of the
HIV viral replication cycle by a combination of drugs
(combined antiretroviral therapy, or cART) reduces
plasma HIV RNA levels to below the limit of detection
of commercial assays (<50 copies/mL) [2,3]. Moreover,
in most patients, cART can also restore CD4 + T cell
counts in blood, thus preventing manifestation of
acquired immunodeficiency syndrome (AIDS).
However, immune dysfunction and chronic inflamma-
tion are not completely resolved during cART.
Inflammation is a defence response to invading
pathogens or endogenous danger signals that contains
and helps to eradicate threats to the organism.
However, if inflammation goes unchecked or persists
in time, it can result in pathology. During HIV infec-
tion, even in cART-treated (virally suppressed) indivi-
duals, parameters of inflammation such as C-reactive
protein [4] and the pro-inflammatory cytokines inter-
leukin (IL)-6 [4], TNF-α and BAFF [5] remain elevated
for long periods of time. These parameters are predic-
tors of a series of clinical conditions collectively known
as serious non-AIDS events (SNAEs) [6], including
cardiovascular disease [7], cancer [8], neurological dis-
ease [9], liver disease [10] and overall mortality [11].
Therefore, understanding the mechanisms underlying
persistent inflammation could lead to the identification
of new targets to reduce the increased risk of SNAEs,
and thus is a priority in HIV research.
Several mechanisms have been proposed to explain
persistent inflammation during HIV infection.
A widely accepted mechanism is the increase in intest-
inal permeability due to the loss of mucosal CD4 + T
cells during early infection with HIV. This results in
the translocation of microbial products, such as lipo-
polysaccharides (LPS), to the circulation, which then
stimulates monocytes/macrophages to secrete pro-
inflammatory molecules [12]. Ongoing HIV replication
and exposure to other microorganisms, like human
cytomegalovirus, may also contribute to persistent
immune activation and inflammation [13,14].
Furthermore, loss of immunoregulatory responses
[15] and lymphoid fibrosis [16] have also been asso-
ciated with markers of inflammation and morbidity.
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Evidence collected during the last few years suggests
that Extracellular Vesicles play important functions in
inflammation, and this will be the central topic of this
Review.
Intercellular communication mediated by EVs
The term Extracellular Vesicle (EV) refers to structures
limited by a lipid bilayer, released by cells into their
extracellular environment, and that contain various
components of the cell of origin. Different types of
EVs have been described, based on their intracellular
biogenesis location [17]. Exosomes are small EVs
(approximately 50–150 nm in diameter) of endosomal
origin that initially form as intraluminal vesicles inside
late endosomal compartments. They are secreted fol-
lowing fusion of the endosomal limiting membrane
with the plasma membrane. Other types of EVs, gen-
erally called ectosomes, microvesicles or microparticles,
are secreted by direct budding from the cellular plasma
membrane, which results in EVs of various diameters:
as small as exosomes (<150 nm) or larger, up to a few
micrometres [18]. Whatever their initial site of forma-
tion, plasma membrane or endosomes, EVs have the
same topological orientation of their limiting mem-
brane as the cell itself: they contain cytosolic compo-
nents and they expose the extracellular domain of
transmembrane proteins inserted into their lipid
bilayer. This structure is identical to that of enveloped
viruses such as HIV, which can thus be considered as
a particular type of EV.
EVs are not a mere reflection of the cell from where
they originate, but they have their own composition
and, therefore, new functions. Indeed, EVs contain
only a selection of the proteins of the secreting cell,
mainly from the plasma membrane, endosomal com-
partments, and cytosolic components, although some
large EVs may also include proteins from other intra-
cellular compartments, such as endoplasmic reticulum
or nucleus [19,20]. Moreover, EVs may contain specific
repertoires of mRNAs and non-coding RNAs, suggest-
ing the existence of mechanisms that control the sort-
ing of these molecules, although these mechanisms are
still unclear [21].
It is generally accepted that following secretion, EVs
mediate the delivery to a target cell of nucleic acids,
lipids and proteins that are expressed on the surface or
contained within the EV lumen, although the actual
mechanisms of such delivery are still poorly under-
stood [18]. Irrespective of the mechanism, it is clear
that EVs can modulate the function of recipient cells,
inducing or suppressing different pathways in physio-
logical and pathological processes [22].
Role of EVs in immunity
EVs mediate communication between cells of the
immune system, participating in the regulation of
immune responses both in normal physiology and
pathological conditions [23,24]. Indeed, EVs can mod-
ulate different aspects and steps of adaptive immune
responses, including antigen presentation [25,26],
T cell polarization [27] and T cell function [28,29]. In
pathological conditions, it has been shown that EVs
can participate in the pathogenesis of autoimmune
diseases [30]. In addition, EVs participate in innate
immune responses, and in particular in inflammation.
It has been shown that EVs secreted both by pathogens
[31–34] and infected cells [35,36] carry pathogen-
associated molecular patterns (PAMPs) and, therefore,
trigger inflammation upon interaction with innate
immune cells. Moreover, EVs containing danger sig-
nals released from stressed or injured cells contribute
to inflammation induction and persistence [37,38].
Additionally, EVs containing cytokines [39–42],
enzymes involved in the biosynthesis of lipid mediators
[43,44] and other chemotactic signals [45] can contri-
bute to the propagation of inflammation.
Role of EVs in viral infections
EVs play diverse and important roles during viral
infections, leading to both pro- and anti-viral effects.
On the one hand, EVs have been shown to contribute
to viral transmission and spread from infected to unin-
fected cells, mainly by masking viral antigens and
PAMPs, thus avoiding immune recognition [46–49].
Remarkably, viruses usually considered as “naked” or
non-enveloped, such as hepatitis A virus (HAV), some
members of the Enterovirus genus, rotavirus, norovirus
and picornavirus were shown to be released from cells
cloaked in host-derived membranes [50–53], facilitat-
ing the delivery of a high level of inoculum to the
receiving host.
In addition to their role in the promotion of viral
transmission, EVs released during viral infections
could contribute to viral replication by dampening
innate antiviral mechanisms, such as natural killer
(NK)-cell functions [47,54,55] and type I interferon
responses [56]. Moreover, EVs can impair adaptive
antiviral immune responses by suppressing Th1
responses [57] or by promoting Treg cell expan-
sion [58].
In contrast to the pro-viral effects mentioned above,
EVs produced by infected cells or by bystander cells
have also been shown to be able to restrict viral repli-
cation by triggering or amplifying host antiviral
responses. Along these lines, it has been shown that
EVs containing HAV [59] and hepatitis C virus RNA
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[60] activate type I interferon responses following
uptake by uninfected plasmacytoid dendritic cells.
Likewise, EVs released by latent Epstein Barr Virus-
infected B cells activated non-infected dendritic cells
(DCs) [61]. In addition, intercellular transmission of
cellular antiviral factors by EVs can also constitute
a mechanism for generating an interferon-induced
antiviral response in non-infected cells, as was
observed for hepatitis B virus [62] and herpes simplex
virus-1 [63] infections. Interestingly, EVs from unin-
fected cells can also restrict viral replication. For
instance, it has been shown that uninfected primary
human trophoblasts, which are highly resistant to viral
infection, can confer EV-mediated antiviral resistance
to different target cells by inducing the autophagy
pathway [64].
In sum, in the complex biology of viral infections,
EVs constitute an intercellular communication
mechanism used both by virus and host, intermingling
antiviral and inflammatory responses with viral spread.
In this sense, understanding the role played by EVs in
HIV infection remains a crucial research goal that will
allow us to gain knowledge on HIV pathogenesis and
to contribute to patient care and treatment strategies.
Considerations regarding limitations in techniques
for separating EVs from virions and for EV isolation
from body fluids
HIV is released from infected cells by a process that in
many aspects resembles the formation of exosomes and
other EVs in non-infected cells. It was thus proposed
already 16 years ago that HIV hijacks the exosome
biogenesis pathway, to hide from the host immune
system by adopting a structure and composition simi-
lar to innocuous endogenous EVs [65]. Similarity of
structure and biophysical properties of small EVs and
HIV (similar diameters of 50–150 nm, similar densities
by flotation in sucrose) makes their separation difficult,
and it is now clearly recognized that they are co-
purified by standard virus or exosomal purification
protocols (differential ultracentrifugation and/or
sucrose cushions) [66,67]. Two techniques have been
used so far to separate endogenous EVs from HIV:
immuno-depletion of the former by anti-CD45 antibo-
dies, since CD45 was described as excluded from the
virus but present in EVs [68], or separation by pelleting
into iodixanol gradients (commercially known as
OptiPrepTM), where the virus reaches the bottom,
dense fractions faster than endogenous EVs [69].
However, both approaches have limitations. Indeed,
we recently observed that, in the T lymphoid cell line
Jurkat, CD45 is mainly released in large EVs, and
hardly present in small EVs. Thus, the utility of CD45
to separate small EVs and/or exosomes from HIV is
limited (LMJ, CT, unpublished results). As for the
velocity gradient, even though HIV is indeed mainly
recovered in the bottom dense fractions, we recently
observed that endogenous EVs are only slightly
“lighter” than the virus, and are recovered in overlap-
ping fractions of such gradient. In addition, by many
different separation approaches, we could show that
acetylcholinesterase (AChE), which was previously
proposed to identify EVs specifically [69], is in fact
mainly present in small non-EV structures recovered
in the light fractions of a velocity gradient, separated
from the overlapping EVs and virions [70]. Thus, some
of the previous attempts at analysing the functions of
EVs in the HIV life cycle (described below in Sections 2
and 3), may have instead established functions of either
co-isolated large EVs (CD45+) or non-vesicular struc-
tures (AChE+), leaving open the question of a role of
small EVs and/or exosomes.
In addition, isolation of vesicles from complex bio-
logical samples, such as blood, poses an extra challenge
due to the presence of other materials that could
diminish EVs preparations purity. That is the case of
plasma samples, which contain large amounts of lipo-
proteins that could be co-isolated with EVs. Moreover,
large proteins and protein aggregates formed in the
plasma also co-precipitate with EVs following ultracen-
trifugation. EV precipitation by polymers (for instance,
by using the commercial kit ExoQuickTM) is not spe-
cific for EVs, and precipitated material certainly
includes non-vesicular components [71]. It is generally
assumed that size exclusion chromatography (SEC)
(probably complemented with density gradient fractio-
nation) is one of the best options available to obtain
highly pure EVs from plasma [72,73]. Therefore, cau-
tion is required when interpreting data obtained for
plasma-purified EVs, since without rigorous demon-
stration of EV purity and assessment of non-EV frac-
tions as controls, it is difficult to argue that a detected
activity is EV-borne and not related to soluble or non-
EV components [71].
Finally, it is important to stress that given the diffi-
culty of analysing the in vivo effect of EVs, together
with the lack of experimental models of HIV infection
other than the primate models, most studies published
on EVs and HIV infection were performed either
in vitro or ex vivo. Thus, evidence supporting in vivo
relevance is scarce.
In the following paragraphs we review the current
knowledge of the functions reported for EVs in the
context of HIV infection. Many of the studies used
separation methods that we now know are not specific
JOURNAL OF EXTRACELLULAR VESICLES 3
for EVs. We will nonetheless describe such studies as
they were presented at the time of their publication.
We will focus especially on the immunomodulatory
effects of EVs and introduce a possible link between
immune activation and cellular metabolism.
Implications of EVs for HIV infection
Effect of EVs on HIV replication in T cells and
macrophages
Using the available, imperfect EV and HIV separation
approaches, some groups have reported different
effects of EVs and the co-isolated HIV particles on
either infectivity or immune responses. In this section,
we will briefly discuss the inhibitory and stimulatory
roles of EVs on HIV infection. A comprehensive
review of these mechanisms has been recently pub-
lished elsewhere [74]. It is striking that EVs can play
both promoting and inhibitory roles in HIV replica-
tion. Although the reasons for these discrepancies are
not clear, they likely reflect the fact that EVs of differ-
ent size, biogenesis and composition are used in the
different studies. The existence of these incongruities
further highlights the need to clearly characterize the
EVs used in each study and the purification method
used to obtain them.
Inhibitory role of EVs during HIV infection
Different mechanisms have been proposed to explain
the observation that EVs produced by HIV-infected
cells are able to inhibit HIV infection of target cells.
For instance, it has been shown that CD4+ EVs pro-
duced by a CD4 + T cell line can inhibit the infectiv-
ity of HIV particles by binding to the viral envelope
protein (gp120), which would thus not be available to
bind to the CD4 receptor expressed on target cells
[75]. In addition, EVs can transfer antiviral effector
molecules to the recipient cells, thus blocking viral
infection or restricting viral propagation. Along these
lines, it has been postulated that infected cells can
transfer family members of the host restriction factor
APOBEC3, thus conferring resistance to HIV infec-
tion to bystander uninfected T cells [76]. However, in
this study, the presence of other factors in EVs that
contribute to HIV inhibition cannot be ruled out.
Finally, Haque et al studied the role of EVs produced
by monocytic cells exposed to cigarette smoke con-
densate (CSC) on HIV-1 replication, showing that
CSC-treated monocytes produce EVs with increased
anti-HIV activity, likely due to modified incorpora-
tion of antioxidant molecules into EVs [77].
EVs have also been implicated as effectors of the
adaptive anti-viral immune response. For instance, it
has been shown that EVs secreted by CD8 + T cells
display potent non-cytotoxic antiretroviral activity by
inhibiting HIV transcription [78].
Concerning the effect of EVs purified from body
fluids, it has been shown that EVs isolated from
semen, breast milk and vaginal fluid have an inhibitory
effect on HIV infection [79–84]. Interestingly, blood
serum-derived exosomes, although internalized by tar-
get cells, were not able to block HIV replication
[80,83].
Promotion of HIV infection/replication by EVs
Another set of studies reported the opposite effect of
EVs on HIV infection, showing that they can act as
facilitators of viral transmission and replication.
A distinctive mechanism by which EVs positively reg-
ulate HIV infection is by mediating the transfer of the
HIV co-receptors CXCR4 and CCR5 to target cells that
do not express these molecules or that express them at
low levels, thus expanding the number of susceptible
target cells [85,86]. Another mechanism that facilitates
HIV transmission is the EV-mediated induction of
maturation of both HIV-infected and bystander non-
infected DCs. Maturation of DCs is accompanied by an
increase of the adhesion molecule ICAM-1, which in
turn facilitates interaction of DCs with CD4 + T cells.
Consequently, lymphocyte activation is promoted, and
transfer of the virus from DCs to CD4 + T cells is
enhanced [87]. Another pro-viral effect has been
described for macrophage-derived EVs, which have
been shown to capture viral particles in clusters, thus
engaging virus-cell interaction and facilitating the
transfer of HIV to neighbouring uninfected cells [88].
Finally, an indirect mechanism through which EVs
promote HIV replication is by mediating the transfer
of HIV-derived proteins or nucleic acids that promote
CD4 + T cell activation, thus rendering them more
permissive to viral infection [89–92].
Effect of EVs on HIV latency/reactivation
While cART typically leads to the reduction of viral
load to undetectable levels, a relatively small but stable
reservoir of latently infected cells persists life-long in
HIV-infected individuals [93]. This reservoir is fully
capable of producing infectious virus when the host
cell is reactivated by antigens, cytokines or when cART
is discontinued. A series of studies have shown that
EVs either from uninfected [94] or HIV-infected
[95,96] cells can reactivate latent HIV infection
through different mechanisms. In contrast, recent evi-
dence from our group has demonstrated an alternative
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possibility of reversing HIV latency by withdrawing
EVs from latently infected U1 and ACH2 cell lines
[97]. Under EV-depleted conditions, these two cell
lines underwent viral reactivation, and further func-
tional analyses indicated that alterations in cellular
lipid production could be a potential underlying
mechanism for this reactivation. In the same study,
we demonstrated that HIV virions produced in the EV-
depleted condition were more infectious, and cells cul-
tured in this depleted condition were more susceptible
to infection [97]. We speculate that the discrepancy
between our observation and the studies that analysed
the role of EVs produced by infected cells on HIV
latency reactivation could be due to the presence of
viral factors, especially Tat, in the EV preparations.
Altogether, these studies suggest that manipulating
EVs in the cellular environment, or modulating cellular
recognition of EVs, could be used to affect HIV
latency.
In summary, these studies using different experi-
mental systems and EVs purified by different meth-
odologies show that vesicles can both inhibit and
promote HIV replication. The use of physiologically-
relevant models and of EVs obtained by standardized
methodologies will help to clarify the role of EVs in
HIV infection in vivo.
EVs and inflammation during HIV infection
As in other chronic inflammatory conditions, such as
rheumatoid arthritis [30,98] and cardiovascular disease
[99], there is an increasing amount of evidence suggest-
ing that EVs constitute potential contributors to
chronic inflammation during HIV infection.
Circulating EVs in HIV patients
EVs have been reported to be more abundant in the
plasma of HIV patients as compared to non-infected
individuals [100–102]. However, since different isola-
tion and quantification methods – not all of them
specific for EVs or properly validated – were used in
these reports, these data should be interpreted with
caution.
In the work by Lee et al., plasma from viraemic and
non-viraemic HIV infected patients as well as from
healthy donors was pooled, and EVs were purified by
differential centrifugation followed by sucrose gradient.
Comparison of EVs purified from the plasma of HIV-
infected subjects with those from uninfected controls
revealed that infected individuals, irrespective of viro-
logical status, had an 18- to 22-fold increase in total
protein content. Nanoparticle Tracking Analysis
(NTA) revealed a similar increase (median 17.9-fold)
in the number of particles for non-viraemic HIV-
infected patients versus healthy controls [100].
Preliminary data from our laboratory (PSP, AR, MO,
unpublished results) also showed higher total protein
content (1.6 fold) in plasma EVs from HIV-infected
individuals purified by SEC followed by centrifugation,
as compared with uninfected controls. In addition, in
longitudinal samples from a well-established simian
immunodeficiency virus (SIV)/macaque model [103],
SEC-separated EVs increased by around 50% from
before infection to acute-phase infection, declined
back to baseline during antiretroviral treatment, and
experienced a transient and slight (<50%) increase dur-
ing treatment interruption (YH and KWW, unpub-
lished data). These longitudinal results suggest the
possibility that at least some of the reported increases
in circulating EVs, particles, or protein are cohort-
specific.
Abundance of EVs in HIV patients was also
observed in other studies where plasma EVs were iso-
lated by EV precipitation [101,102]. These studies also
arrived at the conclusion that HIV-infected individuals
have higher numbers of circulating EVs. However, due
to the methodology used in these studies, it is likely
that non-vesicular material was also present in the
preparations analysed.
Cellular origin of circulating EVs
Cellular origin of EVs circulating in plasma of HIV-
infected individuals is uncertain. A mass spectrometry
analysis of highly purified EVs (isolated from healthy
donor plasma with a combination of iodixanol density
cushion and SEC), detected mostly cell markers for
erythrocytes (CD235a) and platelets (CD41, CD61,
CD62p) [73], thus suggesting that erythrocyte- and
platelet-derived EVs would account for the majority
of plasma vesicles. Nevertheless, contribution of other
cell types such as endothelial cells or lymphocytes to
the mixture of circulating EVs is also likely, as evi-
denced by other analysis methods such as multiplexed
bead-based flow cytometry [104]. Additionally, circu-
lating EVs could be generated from a broad spectrum
of cells, including those of the immune system, upon
activation, stress or apoptotic death.
It has been proposed that HIV-infected T cells
release increased amounts of EVs, an effect mainly
due to the accessory protein Nef. Indeed, Nef expres-
sion was shown to stimulate the release of microvesicle
clusters by HIV-infected cell lines and primary
CD4 + T cells from HIV-infected individuals [105] as
well as from in vitro infected CD4 + T cells [89].
However, the percentage of infected CD4 + T cells in
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HIV+ individuals is too small to account for any
increase in plasma EVs, even if EV secretion is pro-
moted by Nef.
As mentioned above, a hallmark of HIV infection
is chronic immune activation and inflammation,
which are maintained by increased levels of circulat-
ing LPS, among other mechanisms. Remarkably, pro-
inflammatory cytokines and LPS promote EV release
from dendritic cells [106,107] and endothelial cells
[108]. We thus speculate that in HIV-infected
patients, any increase in the number of circulating
EVs comes from a broad population of persistently
activated immune cells, instead of HIV-infected cells
only. Our unpublished data from the SIV/macaque
model mentioned above are supportive of this notion,
showing that during treatment interruption, when
only a small number of cells are infected, the absolute
increase in EVs is much greater than the number of
released viruses. Also supporting this idea, the afore-
mentioned study by Lee et al. suggested a myeloid/
macrophage-like cell population origin of plasma EVs
during HIV infection, according to the cytokine cargo
pattern (e.g. IL-12p40, GRO, NAP-2) [100]. Despite
this indirect evidence, whether activated immune
cells contribute to the increase in circulating EVs
observed in HIV patients in vivo is an interesting
question that needs further investigation.
Pro-inflammatory effects of HIV-related EVs
Several studies suggest that EVs produced during HIV
infection are capable of stimulating inflammation. For
instance, EVs purified by immunoaffinity from the
plasma of HIV-positive subjects incubated with the
monocytic cell line THP-1 exerted transcriptional acti-
vation of genes implicated in interferon responses,
cytokines/chemokines, immune activation, innate
immune responses, and inflammation [101]. Another
study also reported that EVs isolated with ExoQuick
from conditioned medium of HIV-infected U1 cell line
or from serum from HIV+ infected individuals induced
TNFα release by THP-1 cells [109].
TNFα secretion induced by EVs produced during
HIV infection has also been reported by Lee et al. who,
proposed that Nef expression in HEK-293T cells acti-
vated the TNF-converting enzyme ADAM17 and
shuttled it into EVs, which, following uptake by reci-
pient cells, induced pro-TNF cleavage in endosomal
compartments [110]. The same group later described
that ADAM17+ EVs obtained by differential centrifu-
gation from the plasma of cART-treated patients
induced the cleavage of endosomal pro-TNF and its
subsequent secretion in PBMCs and macro-
phages [111].
Our group has recently demonstrated that EVs
released by HIV-infected primary CD4 + T cells pro-
mote pro-inflammatory cytokine production by recipi-
ent CD4 + T cells and monocyte-derived macrophages
[112]. In addition, plasma EVs from HIV-infected
individuals isolated by SEC followed by centrifugation
triggered the release of pro-inflammatory cytokines
(IL-6, IL1-β and TNF-α) by primary monocyte-
derived macrophages [112]. Our results indicate that
EV-mediated inflammation during HIV infection is
coordinated with the activity of the transcription factor
HIF-1α (see below).
Pro-inflammatory cargoes in HIV-EVs
The repertoire of molecules that can be loaded into
EVs is vast, and both viral and host elements could
contribute to the development of inflammation.
Virus-derived pro-inflammatory cargos. The conver-
gence of HIV and EV biogenesis suggests that HIV
products, including RNA and proteins may be packed
within EVs. HIV elements present in EVs could then
contribute to stimulation of immune cells.
As stated above, the viral protein Nef from both
human and simian immunodeficiency virus has been
reported to be incorporated into EVs [89,105,113].
Moreover, almost all Nef in the plasma of HIV patients
was found to be associated with CD45+ EVs [114].
Interestingly, Nef-containing EVs were found even in
the plasma of HIV-infected individuals under antire-
troviral therapy and with undetectable viral loads
[100,114]. The main effect reported for Nef+ EVs on
recipient cells has been the promotion of apoptosis in
primary CD4 + T cells [89] and cell lines [114], which
could contribute to CD4 + T cell depletion. Moreover,
as described above, Nef+ EVs promote TNF-α release
by recipient cells [111]. It should be noted, though, that
some have questioned EV incorporation of Nef [115],
indicating that further studies may be required.
Regarding viral RNA cargo, unspliced HIV genomic
sequences have been identified in EVs obtained by
iodixanol gradient from chronically infected U937
cells [116]. Moreover, viral small RNAs have been
described in EVs released by HIV-infected cells, also
obtained by iodixanol gradient. Trans-activation
response (TAR) RNA was found in EVs derived from
infected Jurkat and primary T cells, predominantly in
a stem-loop form [92]. The same group later demon-
strated that exosomal TAR RNA from HIV-infected
cells was able to modulate the gene expression of pro-
inflammatory cytokines, such as IL-6 and TNF-β, in
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human primary macrophages, through a Toll-like
receptor (TLR) 3-dependent pathway [117]. TAR and
other small RNAs (called by the authors viral miRNAs:
vmiR88 and vmiR99) were also detected in EV-
containing releasate of U1 and infected primary alveo-
lar macrophages, and in sera from HIV+ individuals
precipitated by ExoQuick [109]. Interestingly, in this
work, vmiR88 and vmiR99, but not TAR, stimulated
human macrophage TNFα release in a TLR8-
dependent way. (See, however, discussion of these
mechanisms below.)
Host-derived pro-inflammatory cargoes. EVs pro-
duced during HIV infection have been reported to
contain multiple host-derived inflammatory mediators.
Konadu et al. described that levels of 21 cytokines and
chemokines, such as IL-1α, TNF-α and CXCL10, were
significantly higher in plasma EVs isolated by iodixanol
gradient from HIV-infected patients (n = 15) than in
those from non-infected subjects (n = 10) [118].
Another study analysed plasma EVs isolated by differ-
ential centrifugation plus sucrose gradient, showing
that whereas EVs from healthy donors contained only
3 cytokines/chemokines/soluble factors from a 120-
protein array, those from HIV-infected individuals har-
boured as many as 23 [100]. Moreover, although EVs
from both non-viraemic and viraemic patients exhib-
ited a similar pattern of protein expression, viraemic
patients with low CD4 counts harboured more and
higher levels of pro-inflammatory factors, including
e.g. TNFα, IL-12p40, sIL-6R, sTNF-RI, GRO [100].
Finally, packaging of cytokines and chemokines has
also been shown in EVs derived from the plasma of
HIV-infected alcohol drinkers and cigarette smokers
[119]. Nevertheless, whether these EVs harbouring
inflammatory cytokines exert an effect on recipient
cells has not been explored.
HIV infection and cellular activation may also
induce changes in cell miRNA profiles [120,121],
which could be reflected in EV cargo. Indeed, EVs
from HIV-infected macrophages obtained by iodixanol
gradient were reported to contain 38 miRNAs that
were not present in EVs released by uninfected cells
and 13 upregulated miRNAs [122], amongst which
miR-29a has been described to enhance LPS induced
inflammatory response in macrophages [123]. In addi-
tion, the pro-inflammatory miRNAs miR-155 and
miR-223 were found in EV-containing material preci-
pitated by ExoQuick from the plasma of ART-naive
HIV patients [102].
Altogether, data presented in this section reveal EVs
under the spotlight of possible mechanisms related to the
sustained inflammation in people living with HIV.
A working model depicting the role of EVs in HIV
pathogenesis is presented in Figure 1. Whether EVs are
implicated in the development of SNAES is an open
question that needs further investigation.
HIF-1α and EV production and function
HIF-1α is a transcription factor that was originally
described for its function in controlling the cellular
response to hypoxia [124]. However, further investiga-
tion on the functions of HIF-1α revealed that it is also
associated with development of inflammatory responses.
Indeed, PAMP recognition by myeloid cells activates the
HIF-1α pathway, which plays a key role in regulating
cell aggregation, motility, invasiveness, and bacterial kill-
ing [125]. Furthermore, it has been reported that HIF-1α
promotes the transcription of IL-1β [126], thus directly
contributing to the development of inflammation.
Moreover, HIF-1α was shown to play a critical role in
the induction of trained immunity (the acquisition of
enhanced capability to respond to certain stimuli by cells
of the innate immune system) by fungal components
[127]. Thus, HIF-1α is intimately associated with a pro-
inflammatory activity in macrophages.
Results recently published by our group show that
HIV infection triggers HIF-1α activity in CD4 + T cells,
enhancing viral replication [112]. Remarkably, induction
of HIF-1α activity is not limited to infected CD4 + T
cells because EVs released by these cells, as well as EVs
isolated from the plasma of HIV-infected individuals, in
turn promote HIF-1α activity in bystander lymphocytes
and macrophages. Interestingly, pharmacological inhibi-
tion of the EV-mediated induction of HIF-1α activity in
bystander macrophages reduces the secretion of the pro-
inflammatory cytokines IL-6, IL-1β and TNF-α. Thus,
we postulate that during HIV infection, the induction of
HIF-1α activity, mediated both by the virus and by EVs,
contributes to inflammation.
The coordinated actions of EVs and HIF-1α that we
observe during HIV infection are in line with previous
studies showing the cross-talk between EVs and HIF-1α
activity. For instance, HIF-1α promotes the transcription
of two Rab proteins (Rab22a and Rab27a) that control
intracellular trafficking routes required for EV secretion
[29,128]. Moreover, it has been previously shown that
EVs can promote HIF-1α activity in target cells by
delivering HIF-1α protein [129,130] or a long non-
coding RNA that stabilizes HIF-1α mRNA by prevent-
ing its degradation [131]. Based on our results and those
from other groups, we propose a model where HIF-1α
and EVs coordinately interact to sustain inflammation
during HIV infection (Figure 2).
In conclusion, HIF-1α appears to be a key player
linking metabolic conditions with inflammatory effects
JOURNAL OF EXTRACELLULAR VESICLES 7
in HIV infection, and it could be a potential pharma-
cological target to reduce chronic inflammation in HIV
patients. However, further studies are necessary to
understand the mechanisms by which HIF-1α regulates
the production of pro-inflammatory EVs by HIV-
infected CD4 + T cells, and the effect provoked by
enhanced glycolysis in this process.
Role of EVs in HIV-associated neuroinflammation
Chronic inflammation during HIV infection occurs not
only in the periphery, but also in the central nervous
system [132]. Entering the brain shortly after infection,
usually via infiltrating macrophages [133–136], HIV
productively infects microglia and macrophages [137–
140]. Astrocytes may also be infected, albeit non-
productively [141,142]. The presence of HIV and HIV
proteins provokes release of cytokines and reactive
oxygen species (ROS) from activated cells, whether
infected or not [143–145]. In turn, inflammation con-
tributes to the HIV-associated neurocognitive disorders
(HAND): HIV-associated dementia (HAD or HIV-D),
mild neurocognitive/motor disorders (MND), and
asymptomatic neurocognitive impairment (ANI)
[132,146,147]. While HAD, an AIDS-defining
condition, has become relatively rare as a result of
cART-mediated virologic control, other forms of
HAND persist in effectively treated individuals.
Several roles for EVs have been proposed in HIV-
associated neuroinflammation. Prominently, glial
cells such as astrocytes and microglia have important
modulatory functions in neuroinflammation and
neurodegenerative diseases [148,149] and communi-
cate with other cells through mechanisms that
include EVs. Both harmful and protective effects of
glial EVs have been postulated [150,151].
Interestingly, EVs from both glia and neurons also
reach the periphery, where they may guide immune
responses to brain lesions [152] and serve as biomar-
kers for CNS disease [153,154]. We will now examine
several specific mechanisms attributed to EVs in
HIV-associated neuroinflammation.
Dysregulation of glutamine metabolism could lead to
up-regulation of EV biogenesis and excitotoxicity. One
contribution of EVs to HAND may involve altered
glutamate metabolism. Glutamate is the most abundant
neurotransmitter in the brain but in excess can induce
excitotoxicity [155]. Proinflammatory cytokines such as
Figure 1. Model of chronic inflammation enhanced by extracellular vesicles.
HIV replication or expression of viral components in latently infected cells, in conjunction with bacterial PAMPs released into circulation as
a consequence of microbial translocation in the gut, constitute a persistent activating stimuli for immune cells such as T lymphocytes, monocytes
and macrophages [1]. These activated cells release into circulation EVs containing pro-inflammatory molecules from the host or HIV-derived PAMPs
(as detailed in the enlarged vesicle) [2]. Macrophages exposed to circulating EVs become activated and release inflammatory cytokines [3], which in
turn contribute to a positive loop of systemic chronic inflammation [4].
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IL-1β and TNF-α promote EV release from mouse
astrocytes [156] and from macrophages and microglia
[157], apparently through a glutaminase pathway [158].
Released EVs may also carry and transfer glutaminase
[157]. Dysregulation and translocation of glutaminase
is associated with elevated glutamate levels within the
recipient cell and in the extracellular milieu, driving
excitotoxicity and neuronal cell death [155,159]. These
interesting findings raise several questions for future
studies, such as whether release of glutaminase into the
extracellular space is primarily mediated by EVs and
what the other potentially pro-inflammatory cargoes of
these EVs might be.
EV-associated host and viral small RNAs. Another
mechanism for EV effects in the CNS is the transfer
of miRNAs. In retroviral infection, Yang et al examined
the effects of the HIV Tat protein on astrocytes and
discovered that astrocyte-released EVs promoted
microglial migration [149], a hallmark of CNS innate
inflammatory responses [160]. This effect was
mediated by EV transfer of miR-9 both in vitro and
in vivo, through post-transcriptional regulation of
PTEN [149]. Hu and colleagues reported that
a different host miRNA, miR-29a, was transferred by
EVs and regulated both HIV Tat and morphine-
associated neuronal dysfunction [161]. Finally,
Yelamanchili et al found that EVs induced neurotoxi-
city by shuttling miR-21 to neurons [162]. Specifically,
EV miR-21 exerted its effects by activating TLR7 [162].
EVs may also transfer small RNA fragments derived
from viral transcripts [92,163]. As discussed above,
HIV-infected primary alveolar macrophages were
shown to produce EVs containing small viral RNAs
that elicited TNF-α release by uninfected human
macrophages through TLR8 activation in vitro [109].
Possibly, this could also occur in microglia or macro-
phages of the CNS. Peripheral EVs bearing these small
RNAs might also gain entry into the CNS.
The miRNA and small RNA findings reviewed here
raise the possibility of developing small RNA drugs to
inhibit or enhance identified small RNAs. However,
some of the findings are also puzzling and require
additional investigations. For example, in the case of
the signalling studies, it is difficult to understand how
small RNAs carried inside an EV would engage a toll-
like receptor, since the small RNA and the receptor are
separated by the EV membrane bilayer. Thus, the EV-
Figure 2. Proposed role of HIF-1α in the inflammatory effects in HIV infection.
HIV-1 infection of CD4 + T cells [1] triggers HIF-1α activity, which promotes the transcription of Rab22a and Rab27a [2], thus favouring intracellular
trafficking routes involved in EV secretion [3]. Released EVs, in turn, promote HIF-1α activity in target cells [4], probably by delivering HIF-1α protein,
or a lncRNA that stabilizes HIF-1α mRNA by preventing its degradation. Induction of HIF-1α in EV-recipient CD4 + T cells and macrophages is
required for secretion of pro-inflammatory cytokines [5]. Thus, HIF-1α and EVs coordinately promote inflammation during HIV infection.
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associated small RNA should be somehow transported
across the membrane, or instead, the miRNA and
receptor should remain functional as the EV is
degraded by endosome acidification. Alternatively, the
effects attributed to EV RNA could actually be due to
extra-EV RNA, perhaps enhanced by association with
the surface of the EV.
EVs as carriers of HIV proteins and mediators of
neurotoxicity. Various HIV proteins, even if not incor-
porated into virions, can exert pro-inflammatory and cyto-
toxic effects. Both microglia [164] and astrocytes [165,166]
have been reported to release the HIV accessory protein
Nef in EVs. EV-associated Nef may then induce neuro-
toxicity [166], compromise the blood-brain barrier [164],
or stimulate release of amyloid beta peptide in vitro [167].
HIV Tat may also be released in EVs and induce neuro-
toxicity [168]. Importantly, these studies suggest that HIV
proteins, produced at low levels during replicative latency,
can contribute to chronic inflammation.
In conclusion, EVs appear to contribute to neuroin-
flammation and neurotoxicity in HIV infection in
numerous ways: by influencing metabolism, carrying
miRNAs, and transferring HIV proteins even during
latent infection.
Conclusions and perspectives
The sustained inflammatory state in HIV-infected indi-
viduals is associated with increased morbidity and
mortality. It is generally assumed that chronic inflam-
mation underlies a series of pathologies, including
neurocognitive disorders, vascular dysfunction and
alterations in coagulation state that leads to multimor-
bidity. Understanding the mechanisms responsible for
persistent inflammation, even in patients undertaking
cART, is a priority in the field that could lead to the
development of new therapeutic interventions to
reduce immunopathogenesis.
Increasing evidence suggests that EVs are implicated
in the chronic inflammation observed during HIV
infection. EVs are more abundant in the plasma of
HIV infected individuals. Although it has been pro-
posed that HIV-infected T cells release increased
amounts of EVs, it is possible to speculate that
a broader population of persistently activated immune
cells, such as macrophages, dendritic cells and CD4 + T
lymphocytes, could be responsible for any increase in
the number of circulating EVs. Further research is
needed to corroborate this hypothesis.
EVs isolated from the plasma of HIV-infected patients
present pro-inflammatory effects ex vivo, inducing acti-
vation of monocytes/macrophages and stimulation of
inflammatory cytokines secretion. EVs produced during
HIV infection were shown to contain different pro-
inflammatory cargoes, both virus- and host- derived,
including Nef, viral RNAs, cytokines, chemokines and
inflammatory miRNAs. Unfortunately, widespread use
of imperfect EV separation techniques and the lack of
controls to determine EV purity suggest that caution
should be applied when interpreting many of these stu-
dies. Moreover, as the EV field evolves and markers of
different kinds of vesicles are defined and re-defined,
roles originally assigned to small EVs and/or exosomes
should be reassessed. Despite these limitations, we con-
sider that there is ample evidence for the notion that
circulating EVs have a relevant role in enhancing and
maintaining immune activation and inflammation in
HIV patients. In addition, EVs appear to contribute to
neuroinflammation and neurotoxicity in HIV infection
by influencing metabolism, carrying miRNAs, and trans-
ferring HIV proteins to the CNS even during latent
infection. Nevertheless, whether EVs are also implicated
in the development of SNAEs requires further research.
Interestingly, the transcription factor HIF-1α has
emerged as a possible key player linking EV-secretion
and EV-inflammatory effects in HIV infection. Further
studies addressing the mechanisms underlying the asso-
ciation between HIV infection, increase in HIF-1α activity
and EV-mediated inflammation will undoubtedly contri-
bute to our understanding of HIV immunopathogenesis,
opening a door to the discovery of novel pharmacological
targets to reduce chronic inflammation in HIV patients.
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